Figure 19, Network diagram for network meta-analysis: All discontinuations and discontinuations due to adverse events - Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Donahue KE, Gartlehner G, Schulman ER, et al. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jul. (Comparative Effectiveness Review, No. 211.)

Cover of Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].

Show details

Contents

Figure 19 displays the evidence network for the network meta-analyses of our two discontinuation outcomes: all discontinuations and discontinuations due to adverse events. The diagram graphically displays the number of studies that comprise the evidence base for the analysis and indicates the number of head-to-head and MTX-controlled studies underpinning the pairwise comparisons. The number of trials and participants for each comparison with MTX are as follows: Abatacept (1 trial, N=232), Abatacept plus MTX (2 trials, N=744), Adalimumab plus MTX (1 trial, N=148), Certolizumab plus MTX (2 trials, N=1,195), Etanercept (1 trial, N=632) Etanercept plus MTX (1 trial, N=542), Infliximab plus MTX (3 trials, N=1,098), Methylprednisolone plus MTX (1 trial, N=29), Sulfasalazine (2 trials, N=206), Sulfasalazine plus MTX (2 trials, N=212), Tocilizumab (2 trials, N=792), and Tocilizumab plus MTX (2 trials, N=1,084). The number of trials and participants for the head-to-head comparisons are as follows: Abatacept versus Abatacept plus MTX (1 trial, N=235), Infliximab plus MTX versus Methylprednisolone plus MTX (1 trial, N=30), Sulfasalazine versus Sulfasalazine plus MTX (2 trials, N=210), and Tocilizumab versus Tocilizumab plus MTX (2 trials, N=1,082).

Figure 19Network diagram for network meta-analysis: All discontinuations and discontinuations due to adverse events

MTX = methotrexate; N = number of patients.

From: Results

Contents

Views

Cite this Page
Donahue KE, Gartlehner G, Schulman ER, et al. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jul. (Comparative Effectiveness Review, No. 211.) Figure 19, Network diagram for network meta-analysis: All discontinuations and discontinuations due to adverse events.
PDF version of this title (24M)

Other titles in this collection

AHRQ Comparative Effectiveness Reviews

Recent Activity

Clear Turn Off Turn On

Figure 19, Network diagram for network meta-analysis: All discontinuations and d...
Figure 19, Network diagram for network meta-analysis: All discontinuations and discontinuations due to adverse events - Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on